71935-32-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(Hydroxymethyl)picolinitrile is used as a key intermediate in the synthesis of active pharmaceutical ingredients and drug candidates. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
4-(Hydroxymethyl)picolinitrile is utilized in the production of agrochemicals, where it serves as an essential component in the synthesis of various agrochemical compounds. Its use in this industry helps in the development of effective and innovative solutions for agricultural challenges.
Used in Specialty Chemicals:
4-(HYDROXYMETHYL)PICOLINITRILE is also employed in the production of specialty chemicals, where its versatility and reactivity are harnessed to create unique and high-value chemical products for specific applications across different industries.

InChI:InChI=1/C7H6N2O/c8-4-7-3-6(5-10)1-2-9-7/h1-3,10H,5H2

Upstream product

• 90417-33-7 4-Acetoxymethyl-2-cyanopyridine 
• 117423-43-5 2-cyano-4-[{(tert-butyldimethylsilyl)oxy}methyl]pyridine 
• 22346-75-4 4-pyridylcarbinol-N-oxide 
• 79-44-7 N,N-Dimethylcarbamoyl chloride 
• 7677-24-9 trimethylsilyl cyanide 
• 161233-97-2 2-cyanopyridine-4-carboxylic acid 
• 117423-42-4 4-<<(tert-butyldimethylsilyl)oxy>methyl>pyridine N-oxide 
• 117423-41-3 4-((tert-butyldimethylsilyloxy)methyl)pyridine 
• 586-95-8 pyridine-4-methanol 
• 754218-90-1 2-cyano-4-(trimethylsilyloxymethyl)pyridine 
• 90005-92-8 4-(Acetoxymethyl)pyridine N-oxide 

Downstream Products

• 131747-70-1 2-Cyano-4-pyridinecarboxaldehyde 
• 153993-99-8 4-(bromomethyl)pyridine-2-carbonitrile 
• 108337-90-2 2-(N-Benzyl-N-methylamino)ethyl Methyl 4-(2-Cyano-4-pyridyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate 
• 59663-96-6 ethyl 4-(hydroxymethyl)-pyridine-2-carboxylate 
• 119646-48-9 4-hydroxymethyl-2-pyridinecarboxamide 
• 1148116-92-0 4-(hydroxymethyl)picolinonitrile 4-bromobenzoate 
• 1148116-91-9 4-(hydroxymethyl)picolinonitrile phenylacetate 
• 1148116-93-1 4-(hydroxymethyl)picolinonitrile 4-tert-butylbenzoate 
• 1373423-98-3 4-[(phenyloxy)methyl]-2-pyridinecarbonitrile 
• 1351372-25-2 4-{4-[(4-fluorophenyl)phenylmethoxy]piperidino-1-ylmethyl}pyridine-2-carbonitrile 
• 1351372-26-3 4-{4-[(4-fluorophenyl)phenylmethoxy]piperidin-1-ylmethyl}pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. H

PROBES FOR IMAGING HUNTINGTIN PROTEIN

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST

A heterocyclic compound useful as an antiallergic agent is provided. A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R1 is a carbonyl group or an alkylene group; R2a and R2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R1 is an alkylene group which may have a substituent.

A new photolabile protecting group for release of carboxylic acids by visible-light-induced direct and mediated electron transfer

(Chemical Equation Presented) A new aqueous-compatible photoinduced electron transfer based photolabile protecting group has been developed for the release of carboxylic acids. The reduction potential of this group is more positive than previous systems,

NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT

A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring "A" is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, "B" is alkylene, R1 and R2, the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.

NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS

The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4. The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4.

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

Chemical compounds

The invention relates to quinazoline derivatives of the formula: [wherein: Y1represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R8and R9each independently represents hydrogen, alkyl or alkoxyalkyl); R1represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R2represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R3represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Indole compounds as COX-2 inhibitors

This invention provides a compound of the following formula: and the pharmaceutically acceptable salts thereof, wherein L is oxygen or sulfur; Y is a direct bond or C1-4alkylidene; Q is C1-6alkyl, C3-7cycloalkyl, phenyl, naphthyl, heteroaryl or the like; R1is hydrogen, C1-6alkyl or the like; R2is hydrogen, C1-4alkyl, C(O)R5wherein R5is C1-22alkyl or C2-22alkenyl, halosubstituted C1-8alkyl, halosubstituted C2-8alkenyl, —Y—C3-7cycloalkyl, —Y—C3-7cycloalkenyl, phenyl, naphthyl, heteroaryl or the like; X is halo, C1-4alkyl, hydroxy, C1-4alkoxy or the like; and n is 0, 1, 2 or 3, with the proviso that a group of formula —Y—Q is not methyl or ethyl when X is hydrogen; L is oxygen; R1is hydrogen; and R2is acetyl. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.